Program
BL-ARC002
Its studies are led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 22 open or running | phase 1since May 9, 2026 | May 9, 2026 | Dec 2027phase 1 · NCT07591155 |
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2026First study: phase 1 study in Lung NeoplasmsFirst studyNCT07591155 · 22 planned · China
- Aug 10, 2026Phase 1 study in Digestive System NeoplasmsNCT07763652 · 22 planned · China
Ahead
- Dec 2027Primary completion: phase 1 study in Lung NeoplasmsNCT07591155
- Dec 2028Primary completion: phase 1 study in Digestive System NeoplasmsNCT07763652
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07763652Digestive System Neoplasms · China | 1 | Recruiting | Dec 2028 | 22 |
| NCT07591155Lung Neoplasms · China | 1 | Recruiting | Dec 2027 | 22 |
How it is read
Names in the registry
- “BL-ARC002”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.